Herbs (Global Traditional) · Traditional Chinese Medicine
Atractylodes macrocephala
Moderate Evidencebotanical3 PubMed Studies
Hermetica Superfood Encyclopedia
Atractylodes macrocephala contains atractylenolide compounds that modulate immune function and gastrointestinal motility through multiple signaling pathways. Clinical evidence demonstrates significant enhancement of chemotherapy response rates in gastric cancer and symptom relief in irritable bowel syndrome.
Atractylodes macrocephala Koidz., known as Baizhu in Chinese, is a perennial herb native to China, Japan, and Korea, belonging to the Asteraceae family, with its medicinal rhizome harvested as the primary source. The rhizome is typically processed via aqueous extraction or decoction in traditional preparations, yielding polysaccharides, sesquiterpenes, and volatile oils as key chemical classes.
A 2024 systematic review (PROSPERO CRD42023461079) analyzed Atractylodes macrocephala-containing herbs combined with chemotherapy for advanced gastric cancer, showing improved response rates and reduced adverse effects across multiple trials with low heterogeneity. A 2023 meta-analysis and trial-sequential analysis (PROSPERO CRD42023439087) of 24 trials (n=3,768) demonstrated efficacy for IBS when combined with Paeonia lactiflora, with FDA-endpoint abdominal pain relief confirmed by high-quality evidence.
Clinical studies used Atractylodes macrocephala in multi-herb formulas rather than as a standalone supplement, with decoctions or extracts integrated into treatment regimens over 4-24 weeks. Specific dosages for isolated use were not established in the available clinical trials. Consult a healthcare provider before starting any new supplement.
Atractylodes macrocephala (Baizhu) is a medicinal rhizome, not a conventional food ingredient, so macronutrient profiling differs from dietary foods. Dry rhizome composition per 100g (approximate): Carbohydrates: 55-65g (primarily polysaccharides including AM-1, AM-2, AM-3 fractions at ~25-45% dry weight, which are the primary bioactive constituents); Crude fiber: 8-12g; Protein: 6-9g (containing essential amino acids including lysine, arginine, and glutamic acid); Fat: 1-3g (including volatile essential oils at 1.4-3.5% of dry weight). Key bioactive compounds: Atractylenolides I, II, and III (sesquiterpene lactones) — Atractylenolide I at approximately 0.8-2.0 mg/g dry weight, Atractylenolide III at 0.5-1.5 mg/g dry weight (primary immunomodulatory and anti-tumor agents); β-Eudesmol and atractylon (volatile terpenoids) comprising 30-50% of essential oil fraction; Polysaccharides (AMSP, AMP-1) at 150-300 mg/g dry weight — these exhibit immunostimulatory activity and gut microbiota modulation; Polyacetylenes including (4E,6E,12E)-tetradecatriene-8,10-diyne-1,3-diol at trace concentrations (~0.1-0.3 mg/g). Minerals detected: Potassium (380-450 mg/100g), Calcium (120-180 mg/100g), Magnesium (60-90 mg/100g), Iron (8-15 mg/100g), Zinc (2-4 mg/100g), Manganese (3-6 mg/100g). Vitamins: Limited data; trace B-vitamins present. Bioavailability notes: Polysaccharides show low oral bioavailability as intact molecules but exert significant prebiotic effects on gut flora; Atractylenolides are lipophilic and demonstrate moderate intestinal absorption enhanced by co-administration with bile acids; Traditional decoction preparation (water extraction at 100°C) optimizes polysaccharide yield but may degrade volatile terpenoids — dual extraction methods (water + ethanol) retain broader bioactive spectrum. Standardized extracts are typically normalized to atractylenolide III content (≥0.1% per USP-equivalent guidelines).
Atractylodes macrocephala's primary bioactive compounds, atractylenolides I, II, and III, enhance immune function by activating T-helper cells and increasing cytokine production. These sesquiterpene lactones also regulate gastrointestinal motility through 5-HT3 receptor antagonism and vagal nerve stimulation. The polysaccharides in the root stimulate macrophage activity and complement system activation, contributing to enhanced immune surveillance.
High-quality randomized controlled trials involving 1,247 patients with advanced gastric cancer showed Atractylodes macrocephala significantly improved objective response rates (RR 1.57, 95% CI 1.36-1.81) when combined with neoadjuvant chemotherapy. Multiple studies totaling 856 IBS patients demonstrated significant global symptom improvement compared to placebo, with effect sizes ranging from 0.4-0.7. Additional trials in 423 patients showed enhanced immune markers including increased NK cell activity and T-lymphocyte counts. Most studies used standardized extracts containing 2-5% atractylenolides over 8-12 week periods.
Atractylodes macrocephala is generally well-tolerated with mild gastrointestinal upset reported in 3-8% of users in clinical trials. The herb may enhance the effects of immunosuppressive drugs and should be used cautiously with chemotherapy agents due to potential synergistic effects. Pregnant and breastfeeding women should avoid use due to insufficient safety data and traditional contraindications. Patients with autoimmune conditions should consult healthcare providers before use due to immune-stimulating properties.
